Whole-brain radiotherapy in the management of brain metastasis

Journal of Clinical Oncology

Volumn 24, Issue 8, 2006, Pages 1295-1304

  Khuntia, Deepak ^a   Brown, Paul ^a   Li, Jing ^a   Mehta, Minesh P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; BIS TRIETHYLNITROSOUREA; BROXURIDINE; CORTICOSTEROID; EFAPROXARIL; EFAPROXYN; FLUOROURACIL; GADOLINIUM TEXAPHYRIN; GLIADEL WAFER; LONIDAMINE; MEMANTINE; METHYLPHENIDATE; MISONIDAZOLE; NIMUSTINE; POLYMER WAFER DERIVATIVE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRAIN EDEMA; BRAIN METASTASIS; CANCER RADIOTHERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; EXCITOTOXICITY; HUMAN; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIOSURGERY; REVIEW; BRAIN TUMOR; COGNITION; METASTASIS; MULTIMODALITY CANCER THERAPY; SKULL IRRADIATION;

BRAIN NEOPLASMS; COGNITION; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; RADIATION-SENSITIZING AGENTS; RADIOSURGERY;

EID: 33644850757     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.6185     Document Type: Review

References (107)

1. Wen PY, Black PM, Loeffler JS: Metastatic Brain Cancer, in DeVita V, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippincott, Williams, & Wilkins, 2001, pp 2655-2670
2. Mehta MP, Tremont-Lukats I: Radiosurgery for Single and Mutliple Brain Metastasis, in Sawaya R (ed): Intracranial Metastases: Current Management Strategies. Malden, MA, Blackwell Publishing, Futura Division, 2004, pp 139-164
3. Greenberg H, Chandler WF, Sandler HM: Brain Metastases, in Greenberg H, Chandler WF, Sandler HM (eds): Brain Tumors. New York, NY, Oxford University Press, 1999, pp 299-317
4. Yawn BP, Wollan PC, Schroeder C, et al: Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med 86:32-37, 2003
5. Delattre JY, Krol G, Thaler HT, et al: Distribution of brain metastases. Arch Neurol 45:741-744, 1988
6. Zimm S, Wampler GL, Stablein D, et al: Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 48:384-394, 1981
7. Sundstrom JT, Minn H, Lertola KK, et al: Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 30:296-299, 1998
8. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997
9. Chao JH, Phillips R, Nickson JJ: Roentgenray therapy of cerebral metastases. Cancer 7:682-689, 1954
10. Order SE, Hellman S, Von Essen CF, et al: Improvement in quality of survival following whole-brain irradiation for brain metastasis. Radiology 91: 149-153, 1968
11. Patchell RA, Regine WF: The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat 2:111-115, 2003
12. Arbit E, Wronski M, Burt M, et al: The treatment of patients with recurrent brain metastases: A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer 76:765-773, 1995
13. Prados MD, Scott CB, Rotman M, et al: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: A retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 40:653-659, 1998
14. Prados MD, Seiferheld W, Sandler HM, et al: Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147-1152, 2004
15. Shaw E, Scott C, Suh J, et al: RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases database. J Clin Oncol 21:2364-2371, 2003
16. Mehta MP, Shapiro WR, Glantz MJ, et al: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445-3453, 2002
17. Coia LR: The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys 23:229-238, 1992
18. Harwood AR, Simson WJ: Radiation therapy of cerebral metastases: A randomized prospective clinical trial. Int J Radiat Oncol Biol Phys 2:1091-1094, 1977
19. Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:891-895, 1981
20. Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1-9, 1980
21. Borgelt B, Gelber R, Larson M, et al: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:1633-1638, 1981
22. Chatani M, Teshima T, Hata K, et al: Prognostic factors in patients with brain metastases from lung carcinoma. Strahlenther Onkol 162:157-161, 1986
23. Haie-Meder C, Pellae-Cosset B, Laplanche A, et al: Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 26:111-116, 1993
24. Chatani M, Matayoshi Y, Masaki N, et al: Radiation therapy for brain metastases from lung carcinoma: Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 170:155-161, 1994
25. Murray KJ, Scott C, Greenberg HM, et al: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39:571-574, 1997
26. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280:1485-1489, 1998
27. Bezjak A, Adam J, Barton R, et al: Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38:487-496, 2002
28. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789-796, 1989
29. Khuntia D, Mehta M: Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4:981-989, 2004
30. Carde P, Timmerman R, Mehta MP, et al: Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074-2083, 2001
31. Meyers CA, Smith JA, Bezjak A, et al: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22:157-165, 2004
32. Rodrigus P: Motexafin gadolinium: A possible new radiosensitiser. Expert Opin Investig Drugs 12:1205-1210, 2003
33. Rosenthal Dl, Becerra CR, Toto RD, et al: Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin. Am J Clin Oncol 23:593-598, 2000
34. Mehta MP, Rodrigus P, Terhaard CH, et al: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21: 2529-2536, 2003
35. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, et al: A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: Tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys 49:1133-1139, 2001
36. Kunert MP, Liard JF, Abraham DJ: RSR-13, an allosteric effector of hemoglobin, increases systemic and iliac vascular resistance in rats. Am J Physiol 271:H602-613, 1996
37. Suh JH: Efaproxiral: A novel radiation sensitiser. Expert Opin Investig Drugs 13:543-550, 2004
38. Teicher BA, Wong JS, Takeuchi H, et al: Allosteric effectors of hemoglobin as modulators of chemotherapy and radiation therapy in vitro and in vivo. Cancer Chemother Pharmacol 42:24-30, 1998
39. Stea B, Suh J, Shaw E, Fortin A, et al: Efaproxiral (EFAPROXYN) as an adjunct to whole brain radiation therapy for the treatment of brain metastases originating from breast cancer: Updated survival results of the randomized REACH (RT-009) study. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 4064)
40. Reid JM, Stevens DC, Rubin J, et al: Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following administration of temozolomide to patients with advanced cancer. Clin Cancer Res 3:2393-2398, 1997
41. Patel M, McCully C, Godwin K, et al: Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61:203-207, 2003
42. Abrey LE, Olson JD, Raizer JJ, et al: A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53:259-265, 2001
43. Christodoulou C, Bafaloukos D, Kosmidis P, et al: Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12:249-254, 2001
44. Antonadou D, Paraskevaidis M, Sarris G, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650, 2002
45. Agarwala SS, Kirkwood JM, Gore M, et al: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 22:2101-2107, 2004
46. Siena S, Landonio G, Baietta E, et al: Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer. Proc Am Soc Clin Oncol 22:102, 2003 (abstr 407)
47. Furonaka O, Takeshima Y, Awaya H, et al: Aberrant methylation and loss of expression of O-methylguanine-DNA methyltransferase in pulmonary squamous cell carcinoma and adenocarcinoma. Pathol Int 55:303-309, 2005
48. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004
49. Sze G, Mehta M, Schultz CJ, et al: Radiologic response evaluation of brain metastases: Uni-Dimensional (1d) W.H.O. recist vs. bi-dimensional (2d) or 3-dimensional (3d) criteria. Proc Am Soc Clin Oncol 20:59a, 2001 (abstr 234)
50. Mehta MP, Tsao MN, Whelan TJ, et al: The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 63:37-46, 2005
51. Langer CJ, Mehta MP: Current management of brain metastases, with a focus on systemic options. J Clin Oncol 23:6207-6219, 2005
52. Pirzkall A, Debus J, Lohr F, et al: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16:3563-3569, 1998
53. Smalley SR, Laws ER Jr, O'Fallon JR, et al: Resection for solitary brain metastasis: Role of adjuvant radiation and prognostic variables in 229 patients. J Neurosurg 77:531-540, 1992
54. Aoyama H, Shirato H, Nakagawa K: Interim report of the JROSG99-1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1-4 brain metastases. J Clin Oncol 22:108s, 2004 (abstr 1506)
55. Chougule PB, Burton-Williams M, Saris S: Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. Am Soc Ther Radiat Oncol 48:114, 2000 (abstr 7)
56. Manon R, O'Neill AM, Knisel JP, et al: A phase II trial of radiosurgery (RS) for 1 to 3 newly diagnosed brain metastases from renal cell, melanoma, and sarcoma: An Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 23:8870-8876, 2005
57. Regine WF, Huhn JL, Patchell RA, et al: Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: Results and implications. Int J Radiat Oncol Biol Phys 52:333-338, 2002
58. Meyers CA, Smith JA, Bezjak A, et al: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22:157-165, 2004
59. Meyers CA: Neurocognitive dysfunction in cancer patients. Oncology (Huntington) 14:75-79, 2000; discussion 79
60. Crossen JR, Garwood D, Glatstein E, et al: Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy. J Clin Oncol 12:627-642, 1994
61. Lee AW, Kwong DL, Leung SF, et al: Factors affecting risk of symptomatic temporal lobe necrosis: Significance of fractional dose and treatment time. Int J Radiat Oncol Biol Phys 53:75-85, 2002
62. Mehta MP, Shapiro WR, Glantz MJ, et al: Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445-3463, 2002
63. Mehta MP, Rodrigus P, Terhaard CH, et al: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21: 2529-2536, 2003
64. Gregor A, Cull A, Stephens RJ, et al: Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial: United Kingdom Coordinating Committee for Cancer Res (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 33:1752-1758, 1997
65. Penitzka S, Steinvorth S, Sehlleier S, et al: Assessment of cognitive function after preventive and therapeutic whole brain irradiation using neuropsychological testing. Strahlenther Onkol 178:252-258, 2002
66. Herman MA, Tremont-Lukats I, Meyers CA, et al: Neurocognitive and functional assessment of patients with brain metastases: A pilot study. J Clin Oncol 26:273-279, 2003
67. Meyers CA, Hess KR, Yung WK, et al: Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18: 646-650, 2000
68. Meyers CA, Hess KR: Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression. Neuro-Oncology 5:89-95, 2003
69. Meyers CA, Wefel JS: The use of the minimental state examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557-3558, 2003
70. Laack NN, Brown PD: Cognitive sequelae of brain radiation in adults. Semin Oncol 31:702-713, 2004
71. Spreen O, Struass E: A Compendium of Neuropsychological Tests (ed 2). Oxford University Press, New York, NY, 1998
72. Cohen RA, Moser DJ, Clark MM, et al: Neurocognitive functioning and improvement in quality of life following participation in cardiac rehabilitation. Am J Cardiol 83:1374-1378, 1999
73. Newman MF, Grocott HP, Mathew JP, et al: Report of the substudy assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stroke 32:2874-2881, 2001
74. Meyers C, Boake C: Neurobehavioral disorders experienced by brain tumor patients: Rehabilitation strategies. Cancer Bulletin 45:362-364, 1993
75. Weitzner MA, Meyers CA, Gelke CK, et al: The Functional Assessment of Cancer Therapy (FACT) scale: Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75:1151-1161, 1995
76. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
77. Sheline GE, Wara WM, Smith V: Therapeutic irradiation in brain injury. Int J Radiat Oncol Biol Phys 6:1215-1228, 1980
78. van der Kogel AJ: Radiation-induced damage in the central nervous system: An interpretation of target cell responses. Br J Cancer Suppl 7:207-217, 1986
79. Boldrey E, Sheline G: Delayed transitory clinical manifestations after radiation treatment of intracranial tumors. Acta Radiol Ther Phys Biol 5:5-10, 1966
80. Kramer S: The hazards of therapeutic irradiation of the central nervous system. Clin Neurosurg 15:301-318, 1968
81. Schultheiss TE, Kun LE, Ang KK, et al: Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 31:1093-1112, 1995
82. Chow BM, Li YQ, Wong CS: Radiation-induced apoptosis in the adult central nervous system is p53-dependent. Cell Death Differ 7:712-720, 2000
83. Cammer W: Effects of TNFα on immature and mature oligodendrocytes and their progenitors in vitro. Brain Res 864:213-219, 2000
84. Burger PC, Mahley MS Jr, Dudka L, et al: The morphologic effects of radiation administered therapeutically for intracranial gliomas: A postmortem study of 25 cases. Cancer 44:1256-1272, 1979
85. Monje ML, Palmer T: Radiation injury and neurogenesis. Curr Opin Neurol 16:129-134, 2003
86. Peissner W, Kocher M, Treuer H, et al: Ionizing radiation-induced apoptosis of proliferating stem cells in the dentate gyrus of the adult rat hippocampus. Brain Res Mol Brain Res 71:61-68, 1999
87. DeLong R, Friedman H, Friedman N, et al: Methylphenidate in neuropsychological sequelae of radiotherapy and chemotherapy of childhood brain tumors and leukemia. J Child Neurol 7:462-463, 1992
88. Weitzner MA, Meyers CA, Valentine AD: Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 7:347-350, 1995
89. Meyers CA, Weitzner MA, Valentine AD, et al: Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 16:2522-2527, 1998
90. Lipton SA: Erythropoietin for neurologic protection and diabetic neuropathy. N Engl J Med 350:2516-2517, 2004
91. Ehrenreich H, Hasselblatt M, Dembowski C, et al: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505, 2002
92. Knisely JP, de Lotbiniere AC, de Lotbiniere NC, et al: Randomized trial of erythropoietin as a central nervous system radioprotectant. Int J Radiat Oncol Biol Phys 60:343-344, 2004 (suppl; abstr 2006)
93. Hossain M, Wong CS: Erthropoietin improves learning and memory impairment after whole brain irradiation. Am Assoc Cancer Res 45:724, 2004 (abstr 3125)
94. Rapp SR, Rosdhal R, D'Agostino RB, et al: Improving cognitive functioning in brain irradiated patients: A phase II trial of an acetylcholinesterase inhibitor (donepezil). Neuro-Oncology 6:357, 2004
95. Sano M, Ernesto C, Thomas RG, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222, 1997
96. Chan AS, Cheung MC, Law SC, et al: Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 100:398-404, 2004
97. Armstrong CL, Gyato K, Awadalla AW, et al: A critical review of the clinical effects of therapeutic irradiation damage to the brain: The roots of controversy. Neuropsychol Rev 14:65-86, 2004
98. Wolbach SB: The pathologic history of chronic x-ray dermatitis & early x-ray carcinoma. J Med Res 21:415-449, 1909
99. Belka C, Budach W, Kortmann RD, et al: Radiation induced CNS toxicity-molecular and cellular mechanisms. Br J Cancer 85:1233-1239, 2001
100. Lancelot E, Beal MF: Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 116:331-347, 1998
101. Kornhuber J, Weller M, Schoppmeyer K, et al: Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl 43:91-104, 1994
102. Pellegrini JW, Lipton SA: Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 33:403-407, 1993
103. Chen HS, Pellegrini JW, Aggarwal SK, et al: Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: Therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12:4427-4436, 1992
104. Chen HS, Lipton SA: Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: Uncompetitive antagonism. J Physiol 499:27-46, 1997
105. Chen HS, Wang YF, Flayudu PV, et al: Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86:1121-1132, 1998
106. Orgogozo JM, Rigaud AS, Stoffler A, et al: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 33:1834-1839, 2002
107. Wilcock G, Mobius HJ, Stoffler A, et al: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 17:297-305, 2002